This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
Reduced neutralization of B.1.351 variant SARS-CoV-2 by convalescent sera of COVID-19 patients (preprint)
researchsquare; 2021.
Preprint
in English
| PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-279522.v1
ABSTRACT
SARS-CoV-2 infection raises neutralizing antibodies (NAbs). While studies have shown differing NAb kinetics, they generally point to the antibody arm of immunity providing most recoverees protection against contemporary strains. However, the effect against newly emerged variants of concern (VoCs) has remained uncertain. Here, applying neutralization tests to paired recoveree sera (N=38) of spring 2020 COVID-19 patients with clinical isolates of wildtype D614G and VoC1 and -2 strains (B.1.1.7 and B 1.351) from Finland, we show that NAbs of these patients are equally effective in inhibiting both contemporary and VoC1 strains whereas inhibition of VoC2 is reduced 8-fold (p<0.001) with 50% of sera failing to show NAbs. Our results align with an increased ability of VoC2 to reinfect previously SARS-CoV-infected populations.
Full text:
Available
Collection:
Preprints
Database:
PREPRINT-RESEARCHSQUARE
Main subject:
Severe Acute Respiratory Syndrome
/
COVID-19
Language:
English
Year:
2021
Document Type:
Preprint
Similar
MEDLINE
...
LILACS
LIS